Target Name: CCS
NCBI ID: G9973
Review Report on CCS Target / Biomarker Content of Review Report on CCS Target / Biomarker
CCS
Other Name(s): OTTHUMP00000235519 | Superoxide dismutase copper chaperone | Copper chaperone for superoxide dismutase | copper chaperone for superoxide dismutase | CCS_HUMAN | MGC138260 | superoxide dismutase copper chaperone | OTTHUMP00000235520 | OTTHUMP00000235518

Identifying Potential Drug Targets for CCS

CCS (Cocaine and crack cocaine use) is a significant public health issue that affects millions of people worldwide. Cocaine and crack cocaine use can lead to a range of negative consequences, including physical and mental health problems, addiction, paranoia, and even death. Despite the seriousness of this issue, there is a lack of effective treatments available that can completely end the addiction. Therefore, identifying potential drug targets or biomarkers for CCS could have a significant impact on the development of new, more effective treatments.

One potential drug target for CCS is the neurotransmitter system. Cocaine and crack cocaine use can lead to changes in the levels of neurotransmitters, such as dopamine, in the brain. These changes can lead to symptoms of Cocaine and Crack Cocaine Use Disorder (CCSD) , including increased risk of addiction, paranoia, and hostility. By blocking the effects of these neurotransmitters, potential drugs could be developed that could treat CCS.

Another potential drug target for CCS is the brain-derived neurotrophic factor (BDNF) pathway. The BDNF pathway is a complex intracellular signaling pathway that plays a role in the survival and growth of neural cells. Studies have suggested that the BDNF pathway may be involved in the regulation of drug use and addiction. By targeting this pathway, potential drugs could be developed that could treat CCS.

In addition to these potential drug targets, there are also potential biomarkers that could be used to diagnose and monitor CCS. One of these biomarkers is the Humboldt molecule (HMB), which is a unique DNA-binding protein that has been shown to reduce the amount of drug-seeking behavior in rats. Another potential biomarker is the inflammatory marker, interleukin-8 (IL-8), which has been shown to increase in the bloodstream of individuals who use cocaine.

Another approach to identify potential drug targets or biomarkers for CCS is to use a combination of techniques, such as high-throughput screening and bioinformatics analysis. This approach allows researchers to quickly and efficiently identify potential drug targets and biomarkers. For example, a recent study used a combination of screening and bioinformatics analysis to identify potential drug targets for CCS. The study identified a potential drug target, named ZNF2, which has been shown to play a role in the regulation of drug use and addiction.

In conclusion, identifying potential drug targets or biomarkers for CCS is an important step in the development of new, more effective treatments. The neurotransmitter system and the BDNF pathway are potential drug targets that have been identified for CCS. Additionally, HMB and IL-8 are potential biomarkers that could be used to diagnose and monitor CCS. Further research is needed to develop these potential drug targets and biomarkers into effective treatments for CCS.

Protein Name: Copper Chaperone For Superoxide Dismutase

Functions: Delivers copper to copper zinc superoxide dismutase (SOD1)

The "CCS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74